End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings [PDF]
, 2019 al., et +2 more
core +1 more source
Treatment of Polycythemia Vera: Use of 32P Alone or in Combination With Maintenance Therapy Using Hydroxyurea in 461 Patients Greater Than 65 Years of Age [PDF]
, 1997 Y Najean, Jean‐Didier Rain
openalex +1 more source
Haematological Profile of Patients with Sickle Cell Disease in the Acholi Sub-Region, Uganda. [PDF]
J Blood MedAwor S +10 more
europepmc +1 more source
Biological Evolution in a Homozygous Adult with Sickle Cell Disease on Hydroxyurea: A Case Report
Imane El Khannouri +3 more
openalex +1 more source
The Crystal and Molecular Structure of O-Carbamoylhydroxylamine, an Isomer of Hydroxyurea. [PDF]
, 1968 Ingrid Kjøller Larsen +5 more
openalex +1 more source
Health-related quality of life and adherence to hydroxyurea in patients with sickle cell anemia in Saudi Arabia. [PDF]
Medicine (Baltimore)Abualhommos AK +5 more
europepmc +1 more source
Hydroxyurea pharmacokinetics, it is a small world after all. [PDF]
Blood AdvCaruso C, Appiah-Kubi A.
europepmc +1 more source
Neutralize the neutrophils! Neutrophil β1 /β2 integrin activation contributes to JAK2-V617F–driven thrombosis [PDF]
, 2018 Barbui +4 more
core +2 more sources
DNA polymerase kappa stabilized by Ptbp2 interacts with MRE11 and promotes genomic instability in leukemia. [PDF]
Cell Death DiscovLama S +11 more
europepmc +1 more source